The association between social functioning and cognitive deficits in patients with major depressive disorder in remission state

AimsThis poster aims to examine the impact of social cognitive deficits on psychosocial functioning in depressed patients, as well as summarise the utility of various evidence-based therapeutic interventions employed to target these deficits. The stated hypotheses were twofold: (1) that social cognitive impairment in major depressive disorder will correlate with poorer psychosocial functioning; and (2) that these deficits will respond to existing anti-depressant therapies.BackgroundSocial cognition is an important adaptive trait that incorporates the identification, perception and interpretation of socially relevant information from the external world. It is frequently affected in major depressive disorder such that depressed patienMethodA review of the existing literature was performed in order to test the stated hypotheses. Pertinent sources were identified via the MEDLINE, EMBASE, PsycINFO, PubMed, Scopus and Google Scholar databases. A total of 107 studies met inclusion criteria for review.ResultImpaired social cognitive performance in depressed patients correlated with poorer psychosocial functioning across the key domains of general cognitive functioning and quality of life. Many current anti-depressant therapies were found to have a normalising effect on the social cognitive abilities of depressed subjects, both at a neural and functional level. Anti-depressant medications, in particular citalopram and reboxetine, appeared to correct facial affect recognition deficits, while a psychotherapeutic approach demonstrated improvements in theory of mind and negative interpretive bias. Data relating to other common treatments, such as electroconvulsive therapy, are limited.ConclusionThe impact and treatment of social cognitive deficits in major depressive disorder is an important emerging field. The social cognitive deficits evident in depressed patients are sometimes subtle, but afford a significant functional impact. Additionally, it appears these impairments are at least partially reversible using anti-depressants or psychotherapy.

Download Full-text

Cognitive Deficits in the THINC-Integrated Tool (THINC-it) Are Associated With Psychosocial Dysfunction in Patients With Major Depressive Disorder

The Journal of Clinical Psychiatry ◽

10.4088/jcp.18m12472 ◽

2018 ◽

Vol 80 (1) ◽

Cited By ~ 2

Author(s):

Matthew J. Knight ◽

Célia Fourrier ◽

Ellen Lyrtzis ◽

Natalie Aboustate ◽

Emma Sampson ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Cognitive Deficits ◽

Major Depressive ◽

Psychosocial Dysfunction

Download Full-text

Influence of comorbid anxiety symptoms on cognitive deficits in patients with major depressive disorder

Journal of Affective Disorders ◽

10.1016/j.jad.2019.08.091 ◽

2020 ◽

Vol 260 ◽

pp. 91-96 ◽

Cited By ~ 1

Author(s):

Jin Liu ◽

Qiangli Dong ◽

Xiaowen Lu ◽

Jinrong Sun ◽

Liang Zhang ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Cognitive Deficits ◽

Anxiety Symptoms ◽

Major Depressive ◽

Comorbid Anxiety

Download Full-text

Inflammatory cytokines derived from peripheral blood contribute to the modified electroconvulsive therapy-induced cognitive deficits in major depressive disorder

European Archives of Psychiatry and Clinical Neuroscience ◽

10.1007/s00406-020-01128-9 ◽

2020 ◽

Author(s):

Haihua Tian ◽

Guangxue Li ◽

Guoan Xu ◽

Jimeng Liu ◽

Xiaohan Wan ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Inflammatory Cytokines ◽

Electroconvulsive Therapy ◽

Cognitive Deficits ◽

Peripheral Blood ◽

Major Depressive ◽

Modified Electroconvulsive Therapy

Download Full-text

Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?

Depression Research and Treatment ◽

10.1155/2014/627863 ◽

2014 ◽

Vol 2014 ◽

pp. 1-13 ◽

Cited By ~ 14

Author(s):

Tracy L. Greer ◽

Prabha Sunderajan ◽

Bruce D. Grannemann ◽

Benji T. Kurian ◽

Madhukar H. Trivedi

Keyword(s):

Decision Making ◽

Major Depressive Disorder ◽

Executive Function ◽

Depressive Disorder ◽

Learning And Memory ◽

Cognitive Deficits ◽

Verbal Learning ◽

Small Sample ◽

Major Depressive ◽

Response Control

Introduction. Cognitive deficits are commonly reported by patients with major depressive disorder (MDD). Duloxetine, a dual serotonin/noradrenaline reuptake inhibitor, may improve cognitive deficits in MDD. It is unclear if cognitive improvements occur independently of antidepressant effects with standard antidepressant medications.Methods. Thirty participants with MDD who endorsed cognitive deficits at screening received 12-week duloxetine treatment. Twenty-one participants completed treatment and baseline and posttreatment cognitive testing. The Cambridge Neuropsychological Test Automated Battery was used to assess the following cognitive domains: attention, visual memory, executive function/set shifting and working memory, executive function/spatial planning, decision making and response control, and verbal learning and memory.Results. Completers showed significant cognitive improvements across several domains on tasks assessing psychomotor function and mental processing speed, with additional improvements in visual and verbal learning and memory, and affective decision making and response control. Overall significance tests for executive function tasks were also significant, although individual tasks were not, perhaps due to the small sample size. Most notably, cognitive improvements were observed independently of symptom reduction on all domains except verbal learning and memory.Conclusions. Patients reporting baseline cognitive deficits achieved cognitive improvements with duloxetine treatment, most of which were independent of symptomatic improvement. This trial is registered withNCT00933439.

Download Full-text

Evidence for Progressive Cognitive Deficits in Patients With Major Depressive Disorder

Frontiers in Psychiatry ◽

10.3389/fpsyt.2021.627695 ◽

2021 ◽

Vol 12 ◽

Author(s):

Jin Liu ◽

Bangshan Liu ◽

Mi Wang ◽

Yumeng Ju ◽

Qiangli Dong ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Cognitive Deficits ◽

First Episode ◽

Major Depressive ◽

Illness Duration ◽

Cognitive Components ◽

Significant Difference ◽

Before And After ◽

Mri Study

Background: Cognitive deficits have shown progressive feature in major depressive disorder (MDD). However, it remains unknown which component of cognitive function is progressively impaired across episodes of MDD. Here we aim to identify the progressively impaired cognitive components in patients with MDD.Methods: A comprehensive neurocognitive test battery was used to assess the cognitive components (executive function, attention, processing speed, memory, working memory, inhibition, shifting, and verbal fluency) in 35 patients with first-episode MDD (FED), 60 patients with recurrent MDD (RD) and 111 matched healthy controls (HCs). After 6 months of treatment with antidepressant, 20 FED and 36 RD patients achieved clinical remission and completed their second-time neurocognitive tests. Statistical analyses were conducted to identify the impaired cognitive components in the FED and RD groups before and after treatment, and to assess the relationship between the cognitive components and the number of episodes and total illness duration in the MDD patient group.Results: At baseline, both the FED and RD groups showed impairments in all of the cognitive components; the FED and RD groups showed no significant difference in all of the components except for shifting. After remission, only shifting in the RD group showed no significant improvement and remained in an impaired status. Furthermore, shifting was the only component negatively correlated with the number of episodes as well as the total illness duration.Conclusions: Shifting may serve as the progressive cognitive deficit across episodes of MDD.Clinical Trials Registration: Registry name: HPA function and MRI study of trauma-related depression; Registration number: ChiCTR1800014591; URL: http://www.chictr.org.cn/edit.aspx?pid=24669&htm=4.

Download Full-text